EXEL 伊克力西斯

添加自選

23.460
-0.270-1.14%

收盤價 04/30 16:00 (美東)

21.750
-1.710-7.29%

盤後 19:11 (美東)

69.16億總市值36.09市盈率TTM

關於伊克力西斯公司

Exelixis 是一家發現、開發和商業化癌症治療的生物製藥公司，其先導分子 cabozantinib 以 Cometriq 爲名用於治療轉移性甲狀腺髓樣癌患者，以 Cabometyx 爲名用於治療腎癌和肝癌。 Exelixis 及其合作伙伴羅氏也將 Cotellic 推向了治療黑色素瘤的市場。

公司介紹

公司代碼EXEL

公司名稱伊克力西斯

上市日期2000/04/11

發行價格13.00

成立日期1994

CEODr. Michael M. Morrissey, PhD

所屬市場納斯達克

員工數量1310

證券類型海外普通股

年結日12-29

公司地址1851 Harbor Bay Parkway

城市Alameda

省份加利福尼亞州

國家美國

郵編94502

電話1-650-837-7000

網址http://www.exelixis.com

董事高管

姓名
職務
年薪

Dr. Michael M. Morrissey, PhD
Director, President and Chief Executive Officer
1642.33萬

Dr. Dana T. Aftab, PhD
Chief Scientific Officer and Executive Vice President, Discovery and Translational Research
565.31萬

Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
736.78萬

Christopher J. Senner
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
494.76萬

Patrick J. Haley
Executive Vice President, Commercial
156.47萬

Jeffrey J. Hessekiel
Executive Vice President, General Counsel and Secretary
456.27萬

Dr. Stelios Papadopoulos,PhD
Chairman of the Board
52.00萬

Dr. Sue Gail Eckhardt, M.D.
Director
--

Dr. Mary C. Beckerle, PhD
Director
--

Jacqueline Wright
Independent Director
47.15萬

Julie Anne Smith
Independent Director
49.09萬

Dr. Alan M. Garber, M.D.,PhD
Independent Director
48.12萬

Dr. George H. Poste, D.V.M.,F.R.S.,PhD
Independent Director
43.11萬

Tomas J. Heyman
Independent Director
71.62萬

Jack L. Wyszomierski, M.S.
Independent Director
49.10萬

David E. Johnson
Independent Director
71.87萬

Dr. Maria C. Freire, PhD
Independent Director
48.87萬

Robert Oliver, M.B.A.
Independent Director
71.74萬

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度